How Semaglutide Works: A GLP-1 Receptor Agonist Explained

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. It plays a central role in postprandial glucose homeostasis by stimulating insulin secretion in a glucose-dependent manner. Native GLP-1 has a half-life of only 1–2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Semaglutide, engineered with a C18 fatty acid side chain, binds to albumin in circulation, extending its half-life to approximately 7 days, enabling once-weekly dosing in clinical practice.

The GLP-1 receptor is distributed across multiple tissues, including pancreatic beta cells, alpha cells, the brainstem, and the hypothalamus. This widespread distribution explains semaglutide's pleiotropic effects on glucose regulation, appetite suppression, and potentially cardiovascular outcomes. Research has demonstrated that GLP-1 receptor signaling modulates both peripheral and central appetite regulation pathways.

Semaglutide functions as a selective agonist of the GLP-1 receptor, a G-protein coupled receptor. Upon binding, it activates adenylyl cyclase via Gs protein coupling, increasing intracellular cAMP levels. This cascade triggers downstream signaling that modulates insulin and glucagon secretion in response to circulating glucose. In pancreatic beta cells, semaglutide potentiates glucose-stimulated insulin secretion; in alpha cells, it suppresses glucagon release. Both effects combine to lower fasting and postprandial glucose levels.

The GLP-1 receptor agonism also directly impacts satiety centres in the hypothalamus and brainstem. Neuroimaging and preclinical studies indicate that semaglutide alters appetite signals and food-seeking behaviour through central nervous system pathways. These central effects are thought to be mediated by both direct GLP-1 receptor activation on neurons and indirect modulation of other appetite-regulating neuropeptides including peptide YY and neuropeptide Y.

The GLP-1 receptor is expressed in pancreatic islet cells, the gastrointestinal tract, the central and peripheral nervous systems, and possibly the cardiovascular system. In the pancreas, GLP-1 receptor activation promotes beta-cell glucose sensing and insulin secretion while suppressing alpha-cell glucagon release. In the gastrointestinal tract, it slows gastric emptying and reduces meal size through vagal afferent signaling. In the hypothalamus and brainstem, GLP-1 receptor activation reduces appetite and increases satiety signalling.

Emerging evidence suggests GLP-1 receptors on cardiovascular tissues may contribute to cardioprotective effects observed in clinical trials. Animal models indicate GLP-1 signaling reduces myocardial oxidative stress, improves endothelial function, and may favourably alter cardiac remodelling. However, the relative contribution of peripheral versus central GLP-1 receptor activation to semaglutide's cardiovascular benefits remains an active area of research.

Semaglutide's effects on weight loss involve multiple interconnected metabolic pathways. The primary mechanism is appetite suppression through hypothalamic GLP-1 receptors, leading to reduced caloric intake. Secondary mechanisms include increased energy expenditure—though modest compared to caloric restriction—and improvements in insulin sensitivity. By promoting glucose-dependent insulin secretion and suppressing glucagon, semaglutide reduces hepatic glucose production and improves overall glucose homeostasis, potentially explaining sustained weight loss even after the acute appetite-suppression phase.

At the adipose tissue level, semaglutide may indirectly promote fat oxidation by improving insulin signalling and reducing hyperinsulinaemia. Some preclinical studies suggest direct GLP-1 receptor expression in brown adipose tissue, though the clinical significance remains unclear. The net effect is reduction in body weight, predominantly from fat mass loss, with relative preservation of lean mass during weight loss—an important distinction from simple caloric restriction.

Semaglutide's extended half-life (approximately 7 days) results from its albumin binding via a C18 fatty acid moiety, contrasting with shorter-acting GLP-1 agonists like liraglutide (13 hours) and exenatide (2.5 hours). This pharmacokinetic advantage enables once-weekly dosing, which may improve treatment adherence. Peak plasma concentrations occur 1–3 days post-injection; steady-state is achieved after 4–5 weeks of weekly dosing. The extended half-life also provides a pharmacological buffer, reducing the impact of occasional missed doses.

Semaglutide undergoes hepatic metabolism to smaller peptide fragments and amino acids, with minimal renal excretion of intact peptide. This metabolism profile may be relevant in renal impairment contexts, though clinical data on dosing adjustments remain limited. The long duration of action facilitates once-weekly administration via subcutaneous injection, though oral and intranasal formulations have been investigated in clinical research.

While the GLP-1 receptor agonism is well-established, considerable heterogeneity exists in individual responses to semaglutide. Some patients achieve substantial weight loss (>15% baseline weight) while others show minimal response. The biological basis for this variability—whether genetic, microbiotal, or metabolic—is not fully understood. Additionally, the relative contributions of central versus peripheral GLP-1 signaling to weight loss remain incompletely characterized in humans, limiting precision medicine approaches.

The long-term sustainability of weight loss after semaglutide discontinuation, and the mechanisms underlying weight regain, are areas of ongoing research. Some evidence suggests that cessation of semaglutide leads to rapid weight regain, but whether this reflects loss of pharmacological effect, neural adaptation, or metabolic rebound is not fully resolved. This knowledge gap has clinical implications for long-term treatment planning in weight management.